Overview

The Gene Technology Act 2000 was enacted to establish a regulatory framework for gene technology in Australia, ensuring that activities involving genetically modified organisms (GMOs) are conducted in a manner that protects human health and the environment. This Act was introduced to address the need for a comprehensive system to manage the risks associated with gene technology, particularly in relation to potential environmental impacts and public health concerns. The Act is administered by the Office of the Gene Technology Regulator (OGTR), which is responsible for assessing applications and issuing licences for the use of GMOs. The policy objective of the Act is to balance the potential benefits of gene technology with the need to manage and mitigate any associated risks. The OGTR aims to facilitate the safe and responsible development of gene technology while ensuring public confidence in its regulation.

Scope and Application

The scope of the genetically modified (GM) Indian mustard field trial under consideration by the Gene Technology Regulator (GTR) encompasses entities such as Nuseed Pty Ltd, which has submitted the licence application DIR 149 for evaluation. This application pertains specifically to the limited and controlled release of genetically modified Juncea canola, modified for altered oil content, across designated trial sites within local government areas in New South Wales, Victoria, and Queensland. The trial aims to assess the agronomic performance and oil profile of this GM crop under field conditions, with a proposed timeline from April 2017 to May 2022. Notably, the GM Juncea canola is not intended for human food or animal feed supply, although some GM material may be utilised for small-scale experimental animal feeding studies. The GTR's regulatory framework seeks to mitigate any potential risks to human health, safety, and the environment through the assessment of a Risk Assessment and Risk Management Plan (RARMP). The application of this legislation is geographically confined to the specified areas within the three states, and the GTR is inviting public submissions to contribute to the finalisation of the RARMP, which will subsequently inform the decision on the issuance of the licence.

Key Provisions

The legislation under review, Gazette C2016G01547, pertains to a licence application (DIR 149) submitted by Nuseed Pty Ltd for a field trial of genetically modified Indian mustard (Juncea canola) with altered oil content. This trial, proposed for an extensive period from April 2017 to May 2022, is aimed at evaluating the agronomic performance and oil profile of this GM crop under real-world conditions. The trial sites are to be selected from 102 potential local government areas across New South Wales, Victoria, and Queensland. The trial is planned to commence with a modest scale of up to 2 hectares at four sites in 2017, expanding to five sites covering up to 5 hectares in 2018, and ultimately reaching 15 sites, each up to 10 hectares, in each subsequent year. Notably, the genetically modified crop will not enter the human food or animal feed supply chain, though some GM material may be used for small-scale experimental animal feeding studies. The obligations imposed by this legislation include the preparation of a comprehensive Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human health and the environment. The RARMP must conclude that the proposed release poses negligible risk. Additionally, the Act mandates that draft licence conditions be established to limit the size, location, and duration of the trial, and to restrict the spread and persistence of the genetically modified organisms (GMOs) and the introduced genetic material. The Gene Technology Regulator is tasked with assessing this application and the RARMP to determine whether to issue the licence. The Regulator also encourages written submissions to refine the RARMP before making a final decision. Breach of the conditions stipulated in the licence, if granted, can result in serious consequences. The Act outlines offences and penalties for non-compliance, although specific penalties are not detailed in the Gazette. Typically, violations of gene technology regulations can result in substantial fines and, in severe cases, imprisonment. The Regulator has the authority to impose civil or criminal penalties for breaches, which may include fines up to AU$1.2 million for corporations and AU$220,000 for individuals, along with potential imprisonment terms. The Regulator can also take action to suspend or revoke the licence, effectively halting the trial and potentially leading to further legal consequences for the applicant.